Literature DB >> 6481764

Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma.

B Wappes, M Jennerwein, E von Angerer, H Schönenberger, J Engel, M Berger, K H Wrobel.   

Abstract

Stereoisomeric dichloro [1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes (meso-3a, (+/-)-3b, (+)-3c, (-)-3d) and their N,N'-dibutyl derivatives (meso-4a, (+/-)-4b, (+)-4c, (-)-4d) were synthesized and tested on antitumor activity. The most active compound, 3d, shows a modest inhibition of the [3H]estradiol receptor interaction and causes a marked effect on the growth of the hormone-dependent human MCF 7 breast cancer cell line. It is also active on the hormone-independent human MDA-MB 231 breast cancer cell line, on the ADJ/PC6 plasmacytoma of the Balb/C mouse, and on the L 5222 leukemia of the BD IX rat. Apparently the inhibition of the MCF 7 cell line is not mediated by the estrogen receptor system. Histopathological studies on 3d revealed very low toxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6481764     DOI: 10.1021/jm00376a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.

Authors:  G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat.

Authors:  E von Angerer; H Birnböck; M Kager; A Maucher
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.

Authors:  H D vom Orde; H Reile; R Müller; R Gust; G Bernhardt; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 4.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

5.  [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.

Authors:  G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Influence of ring substituents on the antitumor effect of dichloro(1,2-diphenylethylenediamine)platinum(II) complexes.

Authors:  M Jennerwein; B Wappes; R Gust; H Schönenberger; J Engel; S Seeber; R Osieka
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  Cytotoxic esters of 1,1-bis-(4-hydroxyphenyl)-2-phenyl-but-1-ene with selective antitumor activity against estrogen receptor-containing mammary tumors.

Authors:  M L Schuderer; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 8.  Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues.

Authors:  P C Hydes; M J Russell
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

9.  [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.

Authors:  R Müller; R Gust; G Bernhardt; C Keller; H Schönenberger; S Seeber; R Osieka; A Eastman; M Jennerwein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.